Stereotactic radiation therapy for hepatic malignancies.
Management of primary and secondary tumors of the liver is a complex undertaking involving multi‑disciplinary input. Radiation therapy has played a relatively marginal role in the treatment of liver tumors, but with technological innovations and the growth of the field of stereotactic body radiation therapy (SBRT), this role is evolving. In this review, I discuss the issues of radiation‑induced hepatic toxicity, the planning of liver SBRT treatments, clinical results with SBRT, its place amongst other non‑surgical ablative treatments, and potential future avenues of investigation.
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA - jeffrey.meyer@utsouthwestern.edu.
Jeffrey
J
Meyer
D002986:Clinical Trials as Topic; D019317:Evidence-Based Medicine; D017408:Guidelines as Topic; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology* / Q000532:radiotherapy*; D009367:Neoplasm Staging; D018579:Patient Selection; D016634:Radiosurgery / Q000379:methods; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D016896:Treatment Outcome